出典: meddic


antilipemic agentantilipemic drughypolipidemichypolipidemic agenthypolipidemic druglipid-lowering agentlipid-lowering drug

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Prescribing patterns and economic costs of proton pump inhibitors in Colombia.
  • Machado-Alba J1, Fernández A2, Castrillón JD2, Campo CF2, Echeverri LF2, Gaviria A2, Londoño MJ2, Ochoa SA2, Ruíz JO2.
  • Colombia médica (Cali, Colombia).Colomb Med (Cali).2013 Mar 30;44(1):13-8. eCollection 2013.
  • in

English, SpanishOBJETIVOS: Determinar los patrones de prescripción de inhibidores de la bomba de protones y estimar el costo económico que genera su utilización en pacientes afiliados al Sistema General de Seguridad Social en Salud de Colombia.METODOLOGÍA: Estudio descriptivo observaciona

  • [Drug interactions in the elderly with diabetes mellitus].
  • Hendrychová T1, Vlček J.
  • Vnitr̆ní lékar̆ství.Vnitr Lek.2012 Apr;58(4):299-304.
  • The elderly with diabetes mellitus are usually treated with many types of drugs. This, together with pharmacokinetic and pharmacodynamic changes connected with aging, can lead to an occurrence of drug interactions. They are often manifested as hypoglycaemia, decompensation of diabetes or an increase
  • PMID 22559804
  • Pathogenesis and treatment of human immunodeficiency virus lipodystrophy.
  • Jain SS1, Ramteke KB, Raparti GT, Kalra S.
  • Indian journal of endocrinology and metabolism.Indian J Endocrinol Metab.2012 Mar;16 Suppl 1:S20-6. doi: 10.4103/2230-8210.94250.
  • Enhanced understanding about the way human immunodeficiency virus (HIV) infects and causes infection in humans has led to invention and use of newer more effective antiretroviral drugs. As treatment for HIV is long term, side effects of the antiretrovirals become an important area of research focus.
  • PMID 22701839


  • Evaluation of the phototoxic properties of some hypolipidemics in vitro : fenofibrate exhibits a prominent phototoxic potential in the UVA and UVB region
  • DIEMER Stefan,EBERLEIN-KONIG Bernadette,PRZYBILLA Bernhard
  • Journal of dermatological science 13(2), 172-177, 1996-11-01
  • NAID 10016182382
  • 動脈硬化性疾患患者の血中α-トコフェロールに関する研究
  • 栃原 敏彦,八杉 忠男,清水 隆,小林 功,北田 俊雄,泉田 秀輝,水野 学,田淵 誠一,今野 久忠,波多野 道信
  • 動脈硬化 7(1), 225-231, 1979
  • … (TG), phospholipids (PL), various serum lipoproteins and α-tocophrol (VE) were determined.Results: 1) In hyperlipidemics of both atherosclerotics and controls, distribution of VE within HDL decreased and within LDL increased as compaired with those in normo-or hypolipidemics.2) In the atherosclerotics with or without hyperlipidemia, distribution of VE within HDL decreased and within LDL increased as comparied those in the controls.3) In the hyperlipidemics of both atherosclerotics and controls, quantitative VE content in 1mg of HDL were higher …
  • NAID 130004885174


hypolipidemics.txt · Last modified: 2014/07/03 14:13 by cclarks TUSOM SOM | Medical Pharmacology | TMedWeb ...
This is a wonderful presentation on hypolipidemic drugs by Dr.Sachin Kuchya. Kudos for him. ... Hypolipidemic agents 1. Hypolipidemic Agents Sachin Kuchya, MD Assistant Professor, Department of Pharmacology ...



リンク元lipid-lowering drug」「lipid-lowering agent」「antilipemic drug」「hypolipidemic drug」「antilipemic agent

lipid-lowering drug」


antilipemic agentantilipemic drughypolipidemichypolipidemic agenthypolipidemic drughypolipidemicslipid-lowering agent

lipid-lowering agent」


antilipemic agentantilipemic drughypolipidemichypolipidemic agenthypolipidemic drughypolipidemicslipid-lowering drug

antilipemic drug」


antilipemic agenthypolipidemichypolipidemic agenthypolipidemic drughypolipidemicslipid-lowering agentlipid-lowering drug

hypolipidemic drug」


antilipemic agentantilipemic drughypolipidemichypolipidemic agenthypolipidemicslipid-lowering agentlipid-lowering drug

antilipemic agent」


antilipemic drughypolipidemichypolipidemic agenthypolipidemic drughypolipidemicslipid-lowering agentlipid-lowering drug



  • adj.
  • 脂質低下性の、脂質低下の
  • n.
antilipemic agentantilipemic drughypolipidemic agenthypolipidemic drughypolipidemicslipid-loweringlipid-lowering agentlipid-lowering drug